

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
You can purchase shares of Turn Therapeutics (NASDAQ:TTRX) through any online brokerage.
Other companies in Turn Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Turn Therapeutics has a consensus price target of $14.00.
The stock price for Turn Therapeutics (NASDAQ: TTRX) is $9.8 last updated November 4, 2026 at 4:00 PM EST.
There are no upcoming dividends for Turn Therapeutics.
Turn Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Turn Therapeutics.
Turn Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic,...